Index

A
Abbreviated New Drug Application (ANDA) 79
eCTD submission 79
for generic drugs 79
pre-RFD request 36
regulatory pathway for 39
acceptance review communication (ARC) 97
active and implantable medical devices 147. See also devices
actual-use validation study 63
adverse drug experience (ADE) reporting 122
Advisory Committee (AC) meeting 96
animal pharmacology studies 56
applicants. See combination product applicants
application-based mechanism 49, 50, 51
Assigned Consulted Center Reviewer 93
assignment algorithm
FDA final rule on PMOA 31
for regulatory pathway 35
identification of similar products by 35
legal framework for 32

B
barrier-to-innovation waiver 89
biological product deviation reporting (BPDR) 119
biological product-led combination products.
See drug/biologic-led combination product
Biologic and Radiopharmaceutical Drugs Directorate (BRDD) 130
biologic/biological products
biosimilar or interchangeable products 88
legal framework for definition of 1–7
marketing application for 79
postapproval changes and supplements to 106–108

Biologics Control Act 20
Biologics License Application (BLA)
biologic- or biosimilar-led product 88
constituent part change/supplement submission 109
content of 79
eCTD submission for 79
pathway for 39
pre-RFD request for 36
review process for 95–99
Biologics Price Competition and Innovation Act 88
biosimilar/interchangeable biologic products as constituent parts 88
defined 88
borderline products guidance 150
Bureau of Biologics 17
Bureau of Cardiology, Allergy and Neurological Sciences (BCANS) 133–134
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD) 133–134
Bureau of Medical Sciences (BMS) 134
Bureau of Pharmaceutical Sciences (BPS) 133–134
Bureau of Policy, Science, and International Programs (BPSIP) 134

C
Canada. See also Health Canada
definitions and types of combination products 4
legal framework for combination products 2–3
regulatory authority organization 127
Canada Health Act 128
CE marking 153
Center for Biologics Evaluation and Research (CBER)
creation and mission of 18
eCopy use by 84
leadership chart 21
offices of 20
Center for Devices and Radiological Health (CDRH)
creation and mission of 18
leadership chart 26
offices of 24
Premarket Submission Coversheet for submission 82
responsibilities and offices of 22–24
review divisions of 24, 25
Center for Drug Evaluation and Research (CDER)
creation of 18
eCopy use by 84
leadership chart 23
main offices of 20
mission and functions of 20
OND divisions of 22
Center for Food Safety and Applied Nutrition 18
Center for Tobacco Products 18
Center for Veterinary Medicine 18
Center Product Jurisdiction Officers (PJOs) 94
Centre for Biologics Evaluation (CBE) 131
Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics (CERB) 131
clinical development
 constituent parts evaluation for 58
drug/biological constituent parts 56–58
human factor studies for 64–65
IDE for investigations 57
investigational drugs/biologics 56
manufacturing information 56
protocols for 56
clinical investigations/trials
Clinical Trial Application (CTA) to Health Canada 137
Health Canada application for 137–138
in combination products 46–49
investigational testing authorization (ITA) 137
Clinical Outcome Assessments Staff 22
clinical studies (HF) 64

Combination Product Agreement Meetings (CPAMs)
Lead Center interaction 49
request for 50
submission process for request 52
combination product applicants
definition and types of 115
for constituent parts 116
PMSR information for 123–124
PMSR recordkeeping 122
PSMR recordkeeping for constituent parts 121–122
combination product development
clinical trial design for 46
device constituent parts 45–46
drug/biological products in 45
early FDA interaction for 48–49
information from public sources 48–49
manufacturing of constituent parts 47
marketed constituent parts 44
preclinical testing timeline 46
request and information for CPAM 50
steps in 43
use of data/information not developed by applicant 47–49
combination product identifier 123
combination product regulatory pathways. See also constituent parts
biologic-led 88
borderline products in EU 150
device-led 87–88
drug-led 87
European Union 143
FDA assignment algorithm for 35
FDA Centers responsible for 18
Health Canada 129
in Canada 136
jurisdiction and pathway assignment for 31
lead center determination for 84
postapproval modifications 105
postapproval pathway for change/supplements to 108
postmarket safety reporting 115
pre-request for designation and meetings 35
combination product review process
Inter-Center Consult process 93
marketing applications 95
combination products
borderline cases 150
Canadian 127
CGMP for 67
development of 43
EMA guidelines for 151–153
EU medical device guidelines 150–153
investigational use and human factors 55
legal framework for definition of 1, 3
mode of action in 6
premarket application type 91
pre-request for designation and meetings 37
primary mode of action definition 32
primary review responsibility for 31–41
reconsideration of designation request 35
request for designation 32
RFD and pre-RFD contents 36
types of 3, 5
Combination Products Coalition study 85
Combination Products Policy Council 17
goals of 27
membership 28
Committee for Advanced Therapies (CAT) 145
Committee for Medicinal Products for Human
Use (CHMP) 145
Committee for Medicinal Products for
Veterinary Use (CVMP) 145
Committee for Orphan Medicinal Products
(COMP) 145
Committee on Herbal Medicinal Products
(HMPC) 145
Document (eCTD)
Conformité Européene (CE Mark) 149
conformity assessment of device 150
constituent parts. See also regulatory pathways
and jurisdiction
CGMP requirements for 68
clinical development 58
devices 45–46
drug or biological product 45–46
expiration dating of 75
identifiable mode of action of 31
in combination products 115
legal framework and examples of 4
marketed component in 44
postapproval modification by 111
postmarket change/supplement submission 109
premarket review process/pathway 85–88
safety/efficacy assessment of 46
Consulted Center
resolution of disagreements/questions of 102
responsibilities of 93
Consulted Center Reviewer
constituent parts evaluation 96
in interactive review process 99
container closures vs. delivery device 71
Contergan tragedy 144
contract manufacturing organization (CMO) 72
convenience kits 71
Coordination Group for Mutual Recognition
and Decentralised Procedures-Human
(CMDh) 145, 147
Coordination Group for Mutual Recognition
and Decentralised Procedures-Veterinary
(CMDv 145
coopackaged combination products 4, 68
Cross-Center Dispute Resolution 94
cross-labeled combination products 4, 68
Current Good Manufacturing Practice (CGMP)
combination product subpart of 67
conflict in provisions for 70
design control components examples 74
design control influence on design process 75
design controls 73
device constituent part and 67
expiration dating in 74
investigational products 70
multiple manufacturing facilities 71
single entity and co-packaged combination
products 69
special circumstances 71

D
de novo classification
alternative mechanism for request 83
change summary for 83
postapproval modifications for 112
request format and content for 83–84
Department of Health and Human Service
(HHS) 18
design control/validation
  for use-related hazards 60
human factors testing in 59
in manufacturing process 73
design history file (DHF) 73
device-led combination products
  application-based mechanism examples 50
  non-lead constituent parts in 50
  review process/pathways 87–88, 97
device problem code 123
devices. See also active and implantable medical devices
CGMP exemption of investigational 70
changes and supplement to PMA approved 106–108
eCopy application submissions for 84
EU medical device guidelines 150–153
indications for use changes 106
legal framework for definition 1
premarket notification (510(k)) 39
Director General's Office (DGO) 133
drug/biologic-led combination product
  application-based mechanism examples 51
  medical error and use-related hazards 60
  non-lead constituent parts and 50
  pathway/review process for 88
QSR design control 73
review process/pathways 87
safety/efficacy assessments for 46
drug-device combinations (DDCs) 152
Drug Identification Number 139
drug master files 48
Drug Notification Form (DNF) 139
drugs/medicinal products
  changes and supplements to NDA 105–108
  EU definitions and regulation 148
  legal framework for definition 1
  minor changes to NDA 106
  moderate changes to 106
  MPD definition of 149–153
  premarket applications for 78
  regulatory pathways for 39

E
Economic Free Trade Association (EFTA) 143
electronic Common Technical Document (eCTD)
  for EU marketing authorization 150
legal framework for 81
modular format of 79, 80
electronic copy (eCopy), CDER use of 84
Electronic Medical Device CDER use of (eMDR) 123
Electronic Submissions Gateway (ESG) 79
Emergency Use IND 56
EudraVigilance Expert Working Group 145
EU Medical Device Regulation (EU MDR)
  active implantable devices 147
  combination product regulation 148–153
  conformity assessment requirement 149–153
device definition 2, 147
  transition to 150
European Economic Area (EEA) 143
European Medicines Agency (EMA)
  combination product guidelines 151–153
  device approval 149
  early collaboration and presubmission meetings 16
eCTD use by 79
mission and activities of 144
organization chart for 146
scientific committees of 145
working groups/parties of 145
European Union (EU)
  active and implantable devices 147–148
  combination product regulation in 143
countries and entry dates 144
drug-device combination definitions 4
European Medicines Agency 144
inception of 143
legal framework for combination products 2
medical device definition 147–148
medicinal product definition 148
regulatory framework 148
existing application information for new developer 48
expiration dating 74

F
FDA Adverse Event Reporting System (FAERS) 123
feasibility study 57
Federal Food, Drug, and Cosmetic Act (FD&C Act)
Abbreviated New Drug Application content 79
amendment for combination products 93
dangerous drug administration 20
device definition 32
manufacturing procedure modifications 108
NDA requirements of 78
PMA device changes/supplements 107
premarket notification provision 39

Federal Food, Drug, and Cosmetic Act (FD&C Act)
drug definition 1

Field Alert Reports (FAR) 119
15-day reporting requirements 117–119
filing letter 95–96
five-day report/notification 58, 117–119

(510(k)
content and format for 80
premarket notification for 39

510(k) 39
content and format for 80
equivalence demonstration 87
pathway for devices 39
postapproval modifications to 109
review process for 97–99

505(b)(1). See New Drug Application (NDA)
follow-up reports 118–119

Food and Drug Administration Amendments Act 89

Food and Drug Administration Safety and Innovation Act (FDASIA) 83

Food and Drug Regulations 133, 135, 136

Food and Drugs Act 2, 135

formative studies (HF) 61–65

G
gene therapy products 88

Good Review Management Principles (GRMPs) 95

Guardian/Regulator role (Health Canada) 128
guidance documents/guidelines

Container Closure Systems for Packaging
Human Drugs and Biologics Chemistry 71

Current Good Manufacturing Practice for
Combination Products 67

Current Good Manufacturing Practice
Requirements for Combination Products 47

Deciding When to Submit a 510(k) for a Change to an Existing Device 112

Early Development Considerations for Innovative Combination Products 44

Exploratory IND Studies 57

Good Review Management Principles and Practices for PDUFA Products 95

Guideline on the quality requirements for drug-device combinations 152

How to Prepare a Pre-Request for Designation (Pre-RFD) 36

How to Write a Request for Designation (RFD) 33, 35

Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development 64

Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products—Content and Format 100

Investigational Device Exemptions (IDEs) for Early Feasibility Medical Devices Clinical Studies, Including Certain First in Human (FIH) Studies 58

Management of Applications for Medical Device Licenses 139

Management of Drug Submissions and Applications (Canada) 138

Policy Drug and Medical Device Combination Product Decisions 4

Postmarketing Safety Reporting for Combination Products 116

Requesting FDA Feedback on Combination Products 49

Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA 108

MEDDEV for clinical investigation and labeling 151

MEDDEV for consultation procedures 151

MEDDEV for devices 150

MEDDEV for medicinal products 151

MEDDEV guideline updates 150

Postmarketing Safety Reporting for Combination Products 124
H

Health Canada

Biologic and Radiopharmaceutical Drugs Directorate 130
Bureau of Gastroenterology, Infection and Viral Diseases 133–134
Bureau of Medical Sciences 134
Bureau of Pharmaceutical Sciences 133–134
Bureau of Policy, Science, and International Programs 134
Centre for Biologics Evaluation 131
Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics 131
clinical trials 137
combination product policy 136
combination products definitions and classifications 134
core roles of 128
core values and ethics 127
early collaboration or presubmission meetings 16
cCTD use by 79
Health Products and Food Branch 130
ICH membership 127
Medical Devices Directorate 131
Regulatory Operations and Enforcement Branch 129
Therapeutic Products Directorate 133
Health Products and Food Branch (HPFB) 130
Health Technology 3 (Reproductive, Gastro-Renal, Urological, General Hospital Device and Human Factors), Office of 24
human factors (HF)/usability engineering clinical studies 64–65
considerations in 61
formative studies for 61–65
in design of devices 59
IND or IDE data 64–65
intended use environment 60
interactions of 61
knowledge task studies in 63–65
personal characteristics in 59
validation studies in 62–65

I

indications for use of device, postmarket change to 106

individual case safety reports (ICSRs)
requirements 117–119
Information Provider role (Health Canada) 128
instructions for use (IFU)
FDA requirements for 101
language and content of 101
patient section information in 101
prescription drug or biologic labeling 100
interactive review (IR) 98
intercenter agreements (ICAs) 38
Inter-Center Consult Requests (ICCRs) 85, 86, 93
Inter-Center Consult Review Process 85
International Council of Harmonization (ICH) membership 127
Investigational Device Exemption (IDE) for actual-use studies 63
human factors data in 64
purpose and types of 57–58
investigational new drug (IND) application submission 55
application types 56
clinical development of 56
human factors data in 64
information requirements for 56
investigational testing authorization (ITA) 137
investigational use 55
Investigator IND 56

J

jurisdiction. See regulatory pathways and jurisdiction

K

knowledge task studies (HF) 63–65

L

labeling 78
Canadian regulation of 133
changes or supplements for devices 107
for specific purpose 102
IFUs for patients and caregivers 100
postapproval changes 106
Labeling Policy Team 22
late-cycle meetings 96
Lead Center consult request information 94
primary review responsibility of 85
responsibility of 93
Leader/Partner role (Health Canada) 128

M
malfunction reports 118–119
manufacturing. See also Current Good Manufacturing Practice (CGMP)
guidance for 47–49
information for clinical development 56
multiple facilities for 71
submissions for procedure modifications in 108
marketing authorization/applications 77
biological products 79
CHMP assessment of 145
device submissions 84
drug products 78
Health Canada 138
new drug submission (NDS) 138
review process 95
master files 48
MEDDEV 150. See guidance documents/guidelines
Medical Device License (MDL), Canadian requirements for 139
medical device marketing applications 80
Medical Device Regulation (EU MDR). See EU Medical Device Regulation (EU MDR)
Medical Device Regulations (Canada) 136
medical devices. See devices
Medical Devices Directorate (MDD) 131
Medical Devices Regulations 132, 136
Medical Device Technical Corrections Act (MDTCA) 88
Medical Device Technical Corrections Act (MDTCA) 88
Medical Device User Fee Act (MDUFA) 97
Medical Device User Fee and Modernization Act (MDUfMA) 25
Medical Device User Fee and Modernization Act (MDUfMA) 88
Medical Dictionary for Regulatory Activities (MedDRA) 123
Medicinal Product Directive (MPD)
medicinal product definition 3
medication errors 60
Medicinal Product Directive (MPD)
combination products in 149
product definitions 148
medicinal products. See drugs/medicinal products
meetings
CPAMs 49
EMA early collaboration and presubmission 16
FDA late-cycle 96
FDA mid-cycle 96
FDA presubmission 49
Health Canada early collaboration/presubmission 16
in combination product development 48
in review process 96
pre-RFD 37
mid-cycle meetings 96
minor change 107
mode of action (MOA) 31
determination in EU 6
FDA definition of 31
in product definition 6
in RFD request 34
jurisdiction determination by 31

N
National Center for Toxicological Research 17
Natural Health Products Regulations 135
new chemical entity (NCE) 57
New Drug Application (NDA) 87
changes to approved drugs 105–108
constituent part change submissions 109
content and format for 78
eCTD use for 79
for drug-led product 87–88
for NCE/NME 78
information for review 78–79
pre-RFD request 36
regulatory pathway for 39
review process 95–99
new drug submission (NDS) format and content 138, 139
new molecular entity (NME) 57, 95
nonapplicant PMSR 124
non-ICSR reporting 119
no observed adverse effect level (NOAEL) 46
not substantially equivalent (NSE) decision 80
Office of Blood Research and Review (OBRR) 20
Office of Cardiology, Hematology, Endocrinology and Nephrology, divisions of 22
Office of Clinical Evidence and Analysis 24
Office of Clinical Evidence and Analysis 1 (Clinical Science and Quality) 24
Office of Clinical Evidence and Analysis 2 (Biostatistics) 24
Office of Clinical Policy and Programs (OCPP) 25
Office of Clinical Trials (OCT ) 134
Office of Combination Products (OCP) 17
charter and responsibilities of 25
Consulted Center Receivers list 94
inter-center review coordination by 85
responsibilities of 94
Office of Communication and Education 24
Office of Health Technology 1 (Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices), divisions of 24
Office of Health Technology 2 (Cardiovascular Devices), divisions of 24
Office of Health Technology 4 (Surgical and Infection Control Devices), divisions of 24
Office of Health Technology 5 (Neurological and Physical Medicine Devices), divisions of 25
Office of Health Technology 6 (Orthopedic Devices), divisions of 25
Office of Health Technology 7 (In Vitro Diagnostics and Radiological Health (OIR)), divisions of 25
Office of Immunology and Inflammation and divisions 22
Office of Infectious Diseases, divisions of 22
Office of Management 24
Office of Neuroscience (ON), divisions of 22
Office of New Drugs (OND)
mission and organization of 22
offices and divisions of 22
Office of Nonprescription Drugs, divisions of 22
Office of Oncologic Diseases, divisions of 22
Office of Planning, Performance and Review Services (OPPRS) 134
Office of Policy 24
Office of Product Evaluation and Quality, divisions of 24
Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, divisions of 22
Office of Science and Engineering Laboratories 24
Office of Specialty Medicine, divisions of 22
Office of Strategic Partnerships and Technology Innovation 24
Office of Submission and Intellectual Property (OSIP) 138
Office of the Commissioner 18
Office of Therapeutic Biologics and Biosimilars, divisions of 22
Office of Tissues and Advanced Therapies (OTAT) 20
Office of Vaccines Research and Review (OVRR) 20
Oncology Center of Excellence 18
180-day supplement to PMA 107

P
package insert 78. See labeling
panel-track supplement 107
Paediatric Committee (PDCO) 145, 145–147
pediatric investigation plans (PIPs) 147
Pediatric Regulation 145
periodic safety reporting 118
pharmacokinetic (PK) studies 46
Pharmacovigilance Risk Assessment Committee (PRAC) responsibilities 145
pivotal study 57
PMOA (primary/principle mode/mechanism of action)
Canadian product classification 137
determination of 34
determining lead center for 31
determining lead center for review 102
for combination products in Canada 140
in combination product development 93
Policy on Drug/Medical Device Combination Products 136
postapproval changes/supplementation
changes and supplements to 105
change summary for de novo classification 83
determining submission type for 108
to 510(k) devices 112
postmarketing safety reporting (PMSR)
Field Alert Reports 119
final rule for combination products 115
Individual Case Safety Reports 117–119
information sharing 120
nonapplicant requirements 124
non-ICSR reports 119
recordkeeping for 121
report content requirements 122
requirements for application type 116
same event reporting 122
specific report types 117
streamlined reporting 119
submission of 122
preclinical testing 46
predicate device 83
Premarket Approval Application (PMA)
changes and supplements to devices after 106–108
device-led product review 97–99
format and content for 82
postmarket change/supplement submission 110
pre-RFD request 36
premarket notification (510(k)) 39, 80
premarket review process/pathways 77
constituent parts review for 85–88
premarket 84–88
premarket submission (510(k)) 80
pre-request for designation (RFD)
basic information for 36
listing of components/ingredients and actions 37
preliminary assessment in 36–37
process flow for 38
Prescription Drug User Fee Act (PDUFA) 94
reauthorization of 88
review process goals of 95
pre-submission meetings 49
primary mode of action (PMOA). See PMOA
(primary/principle mode/mechanism of action)
Primary Mode of Action Rule for agency assignment 31
principle mechanism of action (PMOA).
See PMOA (primary/principle mode/mechanism of action)
proprietary name requests 34
Public Health Service Act (PHS Act)
biosimilar submissions 88
BLA established 39
MOA for constituent parts 32
review timeline for BLA/NDA 95
Public Health Service Act (PHS Act)
biologic product definition by 1
manufacturing facilities licensed 20
quality agreements in manufacturing 72
Quality System Regulation (QSR)
legal framework for quality assurance 68
manufacturing procedure changes 108
real-time PMA supplement 107
regulatory intelligence (RI) in strategy development 12
Regulatory Operations and Enforcement Branch (ROEB) 129
regulatory pathways and jurisdiction
classification and center jurisdiction in 39
device-led 87
FDA assignment of 31
intercenter agreements on jurisdiction 38
marketing applications, premarket review pathways, and user fees 77
premarket 78
premarket pathway determination 77
regulatory project manager (RPM)
CDRH submissions 97
communications to reviewers 99–100
communication with applicant 95, 96
in interactive review 98
regulatory strategy
communication with regulators 16
documentation and scope of 9
document elements for submission 13
for combination products 9
in product development 9
regulatory intelligence for 12
regulatory intelligence resources 15
starting point for 10
regulatory strategy document (RSD) 10
content examples for 12
format of 9
sample questions for 11
template for 14
reporter identifier 123

All rights reserved; file sharing prohibited.
International Combination Products

request for designation (RFD)
  proposed uses or indications 34
  regulatory pathway determination 32
  review timeline 35
request for reconsideration of designation 35
review process/pathways
  approval or complete response letter 97
  call to sponsor/applicant 96
  combination products 93
  constituent parts premarket review for
  85–88
  decision communication 99
  ICCR process 94
  interactive review 98
  marketing application 95
  PMOA, lead center, and consulted center for
  84–88
  premarket 77
  substantive interaction 97–99

S
Safe Medical Devices Act (SMDA) 25
same event reporting 122
Service Provider role (Health Canada) 128
simulated-use validation study 62
single-entity combination products 68
small business waiver 89
“Special PMA Supplement-Changes Being
  Effected” 107
Staff Manual Guide (SMG) 4101
  dispute resolution procedures 94
  for review process 85
  Inter-Center Consult Request and Review
  Processes 93
standard operating procedures (SOPs) 9
streamlined approach, CGMP legal framework
  69–70
subject matter expert (SME) developers 55, 57,
  58, 59–60, 61–65, 63, 65
substantially equivalent (SE) device 80
substantive interaction in review process 97
suspected medical product report 122–124

T
Thalidomide tragedy 20
Therapeutic Products Classification Committee
  (TPCC) 135

Therapeutic Products Directorate (TPD)
  Director General's Office 133–134
  functions and offices/bureaus of 133
  30-day notice 108
  toxicity profile studies 46
  for clinical development 56
Treatment IND 56
21st Century Cures Act (Cures Act)
  combination product pathways 93
  meetings combination products 49
  review process 85

U
United States (US) combination product
  definitions 1–3, 3
usability engineering. See human factors (HF)/
  usability engineering
user fees 77
  barrier-to-innovation waiver 89
  legal framework for 88
  small business waiver 89
US Food and Drug Administration (FDA)
  administratives offices 18
  Bureau and Centers evolution 17
  centers and offices of 18
  Centers of 18
  early collaboration or presubmission
    meetings 16
  eCTD use for 79
  food and drug regulations 17–27
  GMP final rule publication 67
  history of 17–27
  jurisdiction of combination products 31
  main offices of 18
  meetings for combination products 49
  mode of action for device assignments 6
  organization leadership chart 19
  structure and overview of 17

V
Vaccine Adverse Event Reporting System
  (VAERS) 123
  “validation period” 95
  validation studies (HF) 62–65